Lehigh Valley Health Network

LVHN Scholarly Works
Department of Obstetrics & Gynecology

RCT Evaluating Safety & Efficacy of Sodium Hyaluronate/
Carboxymethylcellulose at Cesarean Delivery
Daniel G. Kiefer MD
Lehigh Valley Health Network, Daniel_G.Kiefer@lvhn.org

Jolene C. Muscat MD
Jarrett Santorelli BS
Martin R. Chavez MD
Cande V. Ananth PhD, MPH

See next page for additional authors

Follow this and additional works at: https://scholarlyworks.lvhn.org/obstetrics-gynecology
Part of the Obstetrics and Gynecology Commons, Statistics and Probability Commons, and the
Surgery Commons

Published In/Presented At
Kiefer, D., Muscat, J., Santorelli, J., Chavez, M., Ananth, C., Smulian, J., & Vintzileos, A. (2014, April 26). RCT
evaluating safety & efficacy of sodium hyaluronate/carboxymethylcellulose at cesarean delivery. Poster
presented at: The American College of Obstetricians and Gynecologists, Chicago, IL.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion
in LVHN Scholarly Works by an authorized administrator. For more information, please contact
LibraryServices@lvhn.org.

Authors
Daniel G. Kiefer MD; Jolene C. Muscat MD; Jarrett Santorelli BS; Martin R. Chavez MD; Cande V. Ananth
PhD, MPH; John C. Smulian MD, MPH; and Anthony M. Vintzileos MD

This poster is available at LVHN Scholarly Works: https://scholarlyworks.lvhn.org/obstetrics-gynecology/340

RCT Evaluating Safety & Efficacy of Sodium Hyaluronate/Carboxymethylcellulose
at Cesarean Delivery
Daniel G. Kiefer, MD , Jolene C. Muscat, MD , Jarrett Santorelli, BS , Martin R. Chavez, MD , Cande V. Ananth, PhD, MPH , John C. Smulian, MD, MPH , Anthony M. Vintzileos, MD
1

2

3

2

4,5

1

2

Department of Obstetrics and Gynecology, Lehigh Valley Health Network, Allentown, PA; 2Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, NY; 3Department of Obstetrics, Gynecology, and Reproductive Medicine, Stony Brook University, Stony Brook, NY;
4
Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, NY; 5Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, NY

1

ABSTRACT:
Introduction: To determine if placement of sodium hyaluronate/
carboxymethylcellulose (HA-CMC) adhesion barrier (Seprafilm®) at cesarean
delivery reduces adhesion formation at subsequent cesarean delivery. We
previously reported data showing no increase in short-term complications.   
Methods: 753 patients were evaluated in this multicenter, randomized
study. Patients undergoing primary and repeat cesarean deliveries were
randomized into either HA-CMC (N=380) or no-treatment group (N=373).
The location and density of adhesions (primary outcome) were assessed
at their subsequent delivery using a validated tool, which has a score from
0-12. Secondary outcomes included safety and operative times. Sixty-five
patients returning for a subsequent delivery from each arm were required to
show a 50% reduction in adhesions.
Results: No differences in baseline characteristics, post-operative course,
or incidence of complications between the groups following randomization
were noted. Eighty patients from the HA-CMC group and 92 controls
returned for subsequent deliveries. Adhesions in any location were reported
in 75.6% of the HA-CMC group and 75.9% of the controls (P=0.99). There
was no significant difference in the median adhesion score; 2 (range 010) for the HA-CMC group vs. 2 (range 0-8) for the control group (P=0.65).
There were no significant differences in the time from incision to delivery
(P=0.56). Uterine dehiscence in the next pregnancy was reported in 2
patients in HA-CMC group versus 1 in the control (P=0.60).
Conclusion: HA-CMC adhesion barrier applied at cesarean delivery
does not reduce adhesion formation at the subsequent cesarean delivery.
Although we did not demonstrate efficacy for improving adhesion formation,
we did not identify safety concerns.

INTRODUCTION:
• T he cesarean delivery rate continues to rise, resulting
in an increase in adhesive disease.
• Adhesion barriers have been shown to reduce adhesion
formation following other abdominal and pelvic surgery.
• No randomized studies have evaluated the safety or
efficacy of adhesion barriers at the time of cesarean
delivery.
• We report data from a multicenter, randomized,
controlled trial to evaluating the use of  sodium
hyaluronate/carboxymethylcellulose (HA-CMC)
®
(Seprafilm Adhesion Barrier, Sanofi Biosurgery)
following placement at the time of cesarean delivery.
• Short-term safety data were previously reported with
no increase incidence of complications with the use of
HA-CMC.

PROJECT FUNDING:
1. Investigator-Sponsored Trial Grant, Sanofi Biosurgery.
2. PhRMA Foundation Post Doctoral Fellowship in Clinical Outcomes Research Grant.
3. GCRC Grant #MO1RR10710.
NOTE: The funding organizations (including the product manufacturer) had no role in
study design, data collection, analysis, or interpretation, or in the decision to publish
results. The authors designed the project and funding was then sought to support its
execution through investigator-sponsored grants and other available sources.

METHODS:

RESULTS:

• Patient flow diagram is shown in Figure 2.
• A total of 754 patient were randomized to
Seprafilm® (n=380) or no-treatment control
(n=374).
– Lehigh Valley Health Network, Allentown, PA
• There were no differences in baseline demographics
– Winthrop University Hospital, Mineola, NY
or
pre-operative
characteristics
at
the
time
of
– Stony Brook University Medical Center, Stony Brook, NY
randomization (Table 1).
• Inclusion criteria
• Of the randomized patients, 80 from the HA-CMC
– Patients undergoing primary or repeat cesarean delivery
group and 92 controls returned for subsequent
– Age ≥18
deliveries. There were no differences between the
two groups with regard to maternal age, gravidy,
• Exclusion Criteria
parity, or ethnicity.  
– Planned tubal ligation
– Infertility resulting in ≥ 2 years of treatment to achieve current • Delivery was accomplished at a mean gestational
age of 38.6 ± 1.3 weeks for the HA-CMC group
pregnancy
versus 38.4 ± 2.0 for the control (P=0.42).   
– Known allergy to hyaluronic acid
– Pain score ≥5 or IV narcotic administration within two (2) hours • There was similarly no difference in BMI between
prior to consent
the two groups (32.9 ± 8.7 for HA-CMC vs. 33.0 ±
– Medical or other serious condition which will interfere with
6.9 for control group, P=0.972).  
compliance and/or ability to complete study protocol
• Table 2 contains data on the surgical characteristics
• The goal of the adhesion barrier placement was to cover the
of the patients who returned for a subsequent
hysterotomy site, bladder flap (if created) and the midline
delivery, with no significant differences between
anterior surface of the uterus. Physician training on HA-CMC
the two groups.  Notably, there was no difference
placement was provided prior to the beginning of the study and
in skin-to-delivery time, total operative time, or
at any time during the study period at their request.
estimated blood loss.  
• Sample size calculation: The primary endpoint of the study
• Table 3 contains the primary outcome (adhesion
(adhesion formation) was performed with the following
data) at the time of subsequent delivery. Adhesions
assumptions: type I error (alpha) of 0.05, a background risk of
in any location were reported in 75.6% of the HAadhesion of 50% in the no treatment group, and a 25% risk of
CMC group and 75.9% of the controls (P=0.99).
adhesion in the treated group (i.e., a 50% reduction in adhesion
There was no significant difference in the median
formation). A sample size of 65 (of patients who returned for a
adhesion score; 2 (range 0-10) for the HA-CMC
subsequent cesarean delivery) in each arm would be required to
group vs. 2 (range 0-8) for the control group
detect the above difference with 80% power.
(P=0.65).   
• Assessment of adhesion formation: Adhesions were assessed
• We arbitrarily defined “severe adhesions” as the
at the time of randomization utilizing a previously validated
upper quartile for the adhesion score.  One third of
adhesion assessment tool (Figure 1). Participating Institutions
the HA-CMC patients met the definition for severe
modified the Labor and Delivery medical record to begin
adhesions compared to 15.5% in the control group.  
assessing adhesions on every patient delivering at the
•

P
ost-operatively,
hematocrits
(%)
were
similar
(30.4
respective institution.
± 3.1 for HA-CMC vs. 30.0 ± 3.5 for the control,
• Other measures included in this analysis (incision-to-delivery
P=0.44). There was also no difference in the length
time, total operative time, blood loss, etc.) were routinely
of stay (days) following the subsequent delivery
collected for all patients.
(median 3, range 1-9 for HA-CMC vs. median 3,
• The database of enrolled patients was periodically compared
range 1-5 for controls, P=0.51).
to the electronic medical record from each institution to screen
for patients that had returned for a subsequent delivery.  Once
identified, study data was abstracted from their medical record.

• A multicenter, randomized, single blinded (patient), controlled
trial
•	Sites

Figure 1. Adhesion Assessment Scoring

Location

None Filmy Dense

HA-CMC
(n=380)

No Treatment
(n=373)

30.4 ± 5.1

30.9 ± 5.3

Bowel
Uterus to fascia (anterior abdominal wall)

0

1

2

Patient Characteristics

0

1

2

Maternal age (years)*

Omentum to fascia (anterior abdominal wall)

0

1

2

Gravity**

2 (1-20)

2 (1-11)

Omentum to uterus

0

1

2

Parity**

1 (0-4)

1 (0-4)

Baldder to uterus

0

1

2

Race/Ethnicity, % (n)

Other pelvic structure

0

1

2

Caucasian
African-American
Asian
Latino

* Minimum total score = 0; maximum total score = 12
Adopted from Lyell et al. Obstetrics and Gynecology 2005 Aug;106(2):
275-80.

Figure 2. CONSORT Patient Flow Diagram
Enrollment

Assessed for eligibility (n=1670)

Excluded (n=862)
Not meeting inclusion criteria (n=403)
Declined to participate (n=444)
Other reasons (n=15)

Consented (n=808)

Not Randomized (n=55)
Vaginal delivery (n=50)
Revoked consent (n=3)
Other reasons (n=2)

Randomized (n= 753)

Allocation
Allocated to routine closure (n= 373)
Received allocated intervention (n= 373)

Follow-Up
Records Reviewed (n=380)

Records Reviewed (n=373)

Telephone Interview Completed (n=103)

Telephone Interview Completed (n=100)

Analysis
Analyzed for safety data (n=380)
Excluded from analysis (n=0)

Subsequent cesarean delivery (n=80)
Excluded from analysis (n=0)

Other race/ethnicity
Gestational age (weeks)*
Body-mass index (kg/m2)*
Number of previous cesareans**

68.2 (259)
10.3 (39)
3.7 (14)
15.2 (59)

70.6 (264)
10.2 (38)
4.8 (18)
11.5 (43)

2.4 (9)

2.7 (10)

38.7 + 1.9

38.7 + 3.9

33.3 + 6.6

33.2 + 7.8

1 (0, 3)

1 (0, 3)

Indication for cesarean, % (n)

Allocated to HA-CMC (n=380)
Received allocated intervention (n=380)

Table 2. Subsequent Delivery Surgical Characteristics

Table 1. Patient Demographics and Pre-operative Characteristics

Analyzed for safety data (n= 373)
Excluded from analysis (n=0)

Subsequent cesarean delivery (n=92)
Excluded from analysis (n=0)

Patient Characteristics

70.0 (266)

67.0 (250)

2.6 (10)

3.0 (11)

Arrest of labor
Failed induction
Previous uterine surgery
Malpresentation
Abnormal placentation
Multiple gestation
Maternal infection

5.5 (21)
1.8 (7)
1.8 (7)
14.2 (54)
1.3 (5)
4.5 (17)
0.8 (3)

3.2 (12)
3.2 (12)
2.4 (9)
13.9 (52)
2.7 (10)
6.7 (25)
1.3 (5)

Diabetes (any), % of arm (n)
Type I
Type II
Gestational Diabetes, A1
Gestational Diabetes, A2

9.8 (37)

11.8 (44)

0.8 (3)

0.5 (2)

1.0 (4)

0.5 (2)

4.5 (17)

4.8 (18)

3.4 (13)

5.6 (21)

Pre-operative hematocrit*

34.8 + 4.3

34.4 + 5.0

Pre-operative WBC count*
Pre-operative Tmax** (oF)

10.3 + 3.4

10.7 + 4.6

97.8 + 1.0

97.9 + 0.9

* Data are presented as mean (standard deviation) and compared between
groups using the student’s t-test based on unequal between-group
variances.
** Data are presented as median (range), and compared between groups
based on the two-sample median test.

Control (n=92)

Urgency of cesarean, %
Scheduled
Non-emergent
Emergent

p-Value
0.793

78.8
20.0

76.1
20.7

1.3

3.3

20.0

21.7

0.852

Labor prior to operation, %
Rupture of membranes, %
Skin to delivery time (minutes)

6.3

8.7

0.579

8 (1-22)

8 (2-27)

0.973

Total operative time (minutes)

60 (22-112)

58 (15-123)

0.540

15 (1.3)

32 (1.2)

0.941

98.8

96.7

0.624

1.3

2.2

0.999

800 (500-2000)

800 (600-1500)

0.745

8.8 (7)

4.4 (4)

0.665

0.0
5.2 (4)
0.0

0.0
2.3 (2)
0.0

0.423
-

1.3 (1)
0.0
0.0
2.5 (2)

1.1 (1)
0.0
0.0
1.1 (1)

0.999
0.598

Diabetes (%)
Cesarean procedure type, %  
Low transverse
Classical
Estimated blood loss (ml)
Overall complications, % (n)

Planned repeat cesarean
Non-reassuring fetal heart rate

HA-CMC (n=80)

Bladder injury
Bowel injury
Hysterectomy
Intra-operative transfusion
Placenta accreta
Uterine rupture
Uterine dehiscence

Table 3. Subsequent Delivery Adhesion Data (Primary Outcome)

Adhesion Characteristics HA-CMC (n=80)

Control (n=92)

p-Value

2 (0-10)

2 (0-8)

0.647

Any adhesion (any location), %
Bowel adhesions, %
Uterus to fascie, %

75.6

75.9

0.999

5.2

2.3

36.4

26.7

Omentum to fascia, %

32.5

27.9

Omentum to uterus, %

18.2

23.3

Bladder to uterus, %
Other location, %

65.4

62.1

5.2

10.5

Severe adhesions, %

33.3

15.5

Adhesion score*

0.052

* Data are presented as median (range), and compared between groups based on the twosample median test.

DISCUSSION:
• H
 A-CMC adhesion barrier did not reduce the incidence of adhesions at the time of subsequent cesarean delivery.
• There were similarly no difference in operative times or the incidence of complications when HA-CMC was used compared to routine closure.
• This study is important given the frequency of cesarean delivery and the possibility of a rise in adhesion-related complications due to the
historically high cesarean delivery rate.  
• Before incorporating an adhesion barrier (and its associated cost) into routine practice, it is important to vigorously test its ability to achieve the
desired goal.
• Our data do not support routine use of HA-CMC at the time of cesarean delivery.
© 2014 Lehigh Valley Health Network

